U.S., Sept. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07187752) titled 'Identification of HER2-Positive Breast Cancer Molecular Characterization and Subtypes' on Sept. 16.
Brief Summary: This study will evaluate the safety and efficacy of neoadjuvant trastuzumab, pertuzumab and chemotherapy chosen by the investigators and identify the molecular characterization and subtypes in human epidermal growth factor receptor 2 (HER2)-positive breast cancer.
Study Start Date: Sept. 30
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
DRUG: Trastuzumab
Trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks)
DRUG: Pertuzumab
Pertuzumab (loading dose 840 mg, followed by 420 mg ...